A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profile of CBLB502 in Patients With Advanced Cancers.

Trial Profile

A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profile of CBLB502 in Patients With Advanced Cancers.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jan 2016

At a glance

  • Drugs Entolimod (Primary) ; Entolimod (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2015 Status changed from active, no longer recruiting to completed, based on results reported at the 2015 annual meeting of the American Society of Clinical Oncology (ASCO).
    • 01 Jun 2015 Results published in the Cleveland BioLabs media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top